| Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Yokoi, ... New England Journal of Medicine 377 (20), 1919-1929, 2017 | 4115 | 2017 |
| First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer L Horn, AS Mansfield, A Szczęsna, L Havel, M Krzakowski, MJ Hochmair, ... New England Journal of Medicine 379 (23), 2220-2229, 2018 | 2826 | 2018 |
| Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC SJ Antonia, A Villegas, D Daniel, D Vicente, S Murakami, R Hui, T Kurata, ... New England Journal of Medicine 379 (24), 2342-2350, 2018 | 2659 | 2018 |
| Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 1072 | 2020 |
| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 655 | 2017 |
| Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE … N Thatcher, FR Hirsch, AV Luft, A Szczesna, TE Ciuleanu, M Dediu, ... The lancet oncology 16 (7), 763-774, 2015 | 549 | 2015 |
| Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature AA Argyriou, G Iconomou, HP Kalofonos Blood, The Journal of the American Society of Hematology 112 (5), 1593-1599, 2008 | 530 | 2008 |
| Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma … T Powles, MS van der Heijden, D Castellano, MD Galsky, Y Loriot, ... The Lancet Oncology 21 (12), 1574-1588, 2020 | 406 | 2020 |
| A review on oxaliplatin-induced peripheral nerve damage AA Argyriou, P Polychronopoulos, G Iconomou, E Chroni, HP Kalofonos Cancer treatment reviews 34 (4), 368-377, 2008 | 402 | 2008 |
| Adjuvant MAGE-A3 immunotherapy in resected non–small-cell lung cancer: phase II randomized study results J Vansteenkiste, M Zielinski, A Linder, J Dahabreh, EE Gonzalez, ... Journal of Clinical Oncology 31 (19), 2396-2403, 2013 | 373 | 2013 |
| The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings G Cavaletti, DR Cornblath, ISJ Merkies, TJ Postma, E Rossi, B Frigeni, ... Annals of Oncology 24 (2), 454-462, 2013 | 348 | 2013 |
| Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non–small-cell lung cancer: a phase III randomized trial P Kosmidis, N Mylonakis, C Nicolaides, C Kalophonos, E Samantas, ... Journal of clinical oncology 20 (17), 3578-3585, 2002 | 338 | 2002 |
| Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature AA Argyriou, AP Kyritsis, T Makatsoris, HP Kalofonos Cancer management and research, 135-147, 2014 | 321 | 2014 |
| Peripheral nerve damage associated with administration of taxanes in patients with cancer AA Argyriou, M Koltzenburg, P Polychronopoulos, S Papapetropoulos, ... Critical reviews in oncology/hematology 66 (3), 218-228, 2008 | 318 | 2008 |
| Financial crisis and austerity measures in Greece: their impact on health promotion policies and public health care AA Ifanti, AA Argyriou, FH Kalofonou, HP Kalofonos Health policy 113 (1-2), 8-12, 2013 | 305 | 2013 |
| Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial AA Argyriou, E Chroni, A Koutras, J Ellul, S Papapetropoulos, G Katsoulas, ... Neurology 64 (1), 26-31, 2005 | 304 | 2005 |
| Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer AA Argyriou, G Cavaletti, C Briani, R Velasco, J Bruna, M Campagnolo, ... Cancer 119 (2), 438-444, 2013 | 262 | 2013 |
| Either called “chemobrain” or “chemofog,” the long-term chemotherapy-induced cognitive decline in cancer survivors is real AA Argyriou, K Assimakopoulos, G Iconomou, F Giannakopoulou, ... Journal of pain and symptom management 41 (1), 126-139, 2011 | 258 | 2011 |
| Carboplatin plus paclitaxel in unknown primary carcinoma: a phase II Hellenic Cooperative Oncology Group Study E Briasoulis, H Kalofonos, D Bafaloukos, E Samantas, G Fountzilas, ... Journal of clinical oncology 18 (17), 3101-3107, 2000 | 253 | 2000 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised … DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet 390 (10109), 2266-2277, 2017 | 247 | 2017 |
